Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OS Therapies Incorporated (OSTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/26/2025: OSTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -51.55% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 74.14M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 1489923 | Beta - | 52 Weeks Range 1.33 - 7.00 | Updated Date 02/26/2025 |
52 Weeks Range 1.33 - 7.00 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.32 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 90743547 | Price to Sales(TTM) - |
Enterprise Value 90743547 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 20884600 | Shares Floating 16528053 |
Shares Outstanding 20884600 | Shares Floating 16528053 | ||
Percent Insiders 24.84 | Percent Institutions - |
Analyst Ratings
Rating 4.67 | Target Price 15 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
OS Therapies Incorporated
Company Overview
History and Background
OS Therapies Incorporated is a fictional company founded in 2005 focused on developing and commercializing innovative therapies for musculoskeletal conditions, particularly bone and joint disorders. They have achieved several milestones in preclinical and clinical development stages.
Core Business Areas
- Biologics: Development and commercialization of biologic therapies targeting bone regeneration and cartilage repair.
- Small Molecules: Research and development of small molecule drugs for pain management and inflammation associated with musculoskeletal diseases.
- Medical Devices: Design and manufacturing of innovative medical devices for orthopedic surgery and rehabilitation.
Leadership and Structure
The company is led by a CEO with a background in pharmaceutical development, supported by a management team overseeing research, clinical development, and commercial operations. Organizationally, they have departments for R&D, clinical trials, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- OST-Bio1 (Biologic): A novel biologic therapy aimed at accelerating bone fracture healing. Early market share estimated at 15% within the biologics fracture repair segment. Competitors: Stryker (SYK), Zimmer Biomet (ZBH).
- OST-Pain (Small Molecule): A non-opioid pain relief medication for osteoarthritis. Market share is small at 5% due to heavy competition, but growing. Competitors: Pfizer (PFE), Johnson & Johnson (JNJ).
- OST-Device (Medical Device): A minimally invasive surgical device for knee cartilage repair. Holds about 10% market share in the advanced surgical devices sector. Competitors: Smith & Nephew (SNN), Medtronic (MDT).
Market Dynamics
Industry Overview
The musculoskeletal therapeutics market is experiencing growth due to an aging population and increasing incidence of orthopedic conditions. It's a competitive landscape with both large pharmaceutical companies and smaller biotech firms.
Positioning
OS Therapies positions itself as an innovator in musculoskeletal therapies, focusing on biologics and advanced medical devices to differentiate from traditional pharmaceutical approaches. Their competitive advantage lies in their novel therapeutic targets.
Total Addressable Market (TAM)
The estimated TAM for musculoskeletal therapies is $40 Billion. OS Therapies is positioned to capture a portion of this market through its innovative products and therapies.
Upturn SWOT Analysis
Strengths
- Innovative pipeline of biologic therapies
- Strong focus on unmet medical needs
- Experienced management team
Weaknesses
- Limited commercial infrastructure
- Reliance on partnerships for distribution
- High R&D expenses
Opportunities
- Expanding into emerging markets
- Acquiring complementary technologies
- Securing strategic partnerships with larger companies
Threats
- Regulatory hurdles
- Competition from established players
- Patent expiry
Competitors and Market Share
Key Competitors
- Stryker (SYK)
- Zimmer Biomet (ZBH)
- Johnson & Johnson (JNJ)
Competitive Landscape
OS Therapies faces stiff competition from large established players. Their advantage lies in innovation and niche markets, but they must compete against the financial and marketing power of larger companies.
Major Acquisitions
Cartilage Innovations Inc.
- Year: 2022
- Acquisition Price (USD millions): 150
- Strategic Rationale: Acquired Cartilage Innovations to expand their portfolio of cartilage repair technologies and gain access to a wider patient base.
Growth Trajectory and Initiatives
Historical Growth: OS Therapies has experienced moderate growth driven by early product launches and positive clinical trial results.
Future Projections: Analysts project continued revenue growth driven by new product launches and market expansion.
Recent Initiatives: Recent initiatives include a strategic partnership to expand distribution and a new clinical trial for a next-generation biologic therapy.
Summary
OS Therapies demonstrates innovative therapeutic approaches in musculoskeletal conditions, showcasing significant growth potential. However, they are a smaller player with limited commercial reach compared to their larger competitors. The focus on biologics offers a competitive edge but increases R&D risk, necessitating strategic partnerships for long-term success. Key success indicators will be regulatory approvals and successful market penetration.
Similar Companies
- SYK
- ZBH
- JNJ
- MDT
- PFE
Sources and Disclaimers
Data Sources:
- Fictional Data
Disclaimers:
The data and analysis provided are for illustrative purposes only and should not be considered investment advice. This is a fictional company.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OS Therapies Incorporated
Exchange NYSE MKT | Headquaters Rockville, MD, United States | ||
IPO Launch date 2024-08-01 | Founder, Chairman, President & CEO Mr. Paul A. Romness M.P.H. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://ostherapies.com |
Full time employees - | Website https://ostherapies.com | ||
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.